(MedPage Today) -- Cefazolin was effective for the treatment of bacteremia caused by methicillin-susceptible Staphylococcus aureus (MSSA), findings of an international open-label platform trial showed. Among patients hospitalized with penicillin...
(MedPage Today) -- The Federal Trade Commission (FTC) and four states sued the World Professional Association for Transgender Health Wednesday, in the latest push by President Donald Trump's administration and others to limit gender-affirming care...
(MedPage Today) -- Welcome to Culture Clinic, MedPage Today's collaboration with Northwell Health to offer a healthcare professional's take on the latest viral medical topics. In the hit TV show "Ted Lasso," there was an ongoing joke that the...
(MedPage Today) -- Treating opioid withdrawal with short-acting opioids showed a dose-dependent association with a reduction in early patient-directed discharge in hospitalized adults receiving medications for opioid use disorder (OUD), according...
(MedPage Today) -- The FDA approved oral tebipenem pivoxil (Utebzi) as the first oral carbapenem antibiotic to treat complicated urinary tract infections (UTIs), the agency announced on Wednesday. Tebipenem pivoxil is indicated for complicated...
(MedPage Today) -- Science has always been political. From the people who have been allowed to dominate research and academic spaces, to the diseases we study and prioritize funding for. I am a soon to be third-year MD-PhD student. My doctoral...
(MedPage Today) -- CHICAGO -- Menopausal hormone therapy was associated with a reduced risk of low bone mineral density (BMD) among postmenopausal women in a retrospective cohort study. Among the 387 women analyzed, low BMD -- defined as osteopenia...
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. on Wednesday announced a $700 million investment into behavioral health programs, indicating an emphasis on faith-based recovery organizations. Kennedy, a recovered heroin addict, announced a $96 million funding opportunity for the Trump administration's Safety Through Recovery, Engagement, and Evidence-based Treatment and Support (STREETS) program, along...
UniQure is preparing to seek accelerated FDA approval for its Huntington’s disease gene therapy, a move that follows the FDA’s reversal of its prior position calling for another clinical trial. This gene therapy is the latest in a growing list of rare disease treatments to receive reconsideration from an FDA that appears to be swinging back to regulatory flexibility. The post FDA Reversal on uniQure Gene Therapy Is Another Sign of Renewed Regulatory Flexibility appeared first on MedCity News .